Objective: To evaluate the incidence and prevalence of autoimmune encephalitis and compare it to that of infectious encephalitis. Methods: We performed a population-based comparative study of the incidence and prevalence of autoimmune and infectious encephalitis in Olmsted County, Minnesota. Autoimmune encephalitis diagnosis and subgroups were defined by 2016 diagnostic criteria, and infectious encephalitis diagnosis required a confirmed infectious pathogen. Age-and sex-adjusted prevalence and incidence rates were calculated. Patients with encephalitis of uncertain etiology were excluded.
the number of validated autoantibody biomarkers of encephalitis has increased dramatically. Awareness of the epidemiology of autoimmune encephalitis is essential for allocation of resources and health care planning. The diagnostic criteria for autoimmune encephalitis and its subcategories published in 2016 are utilized in this study. 6 Herein, we describe the incidence and prevalence of autoimmune encephalitis in Olmsted County (Minnesota), a geographically defined region of the USA, and compare the epidemiology of autoimmune encephalitis and infectious encephalitis.
Patients and Methods

Study Design and Participants
For this population-based study of the incidence and prevalence of autoimmune encephalitis among residents of Olmsted County, Minnesota, we included patients of both sexes and all ages, including children and ethnic minorities. The study was approved by the institutional review boards of the Mayo Clinic and Olmsted Medical Center. Olmsted County in southeastern Minnesota (USA) has a population of 155,285 (January 1, 2014), primarily of northern European descent, and includes the city of Rochester. The medical records linkage system of the Rochester Epidemiology Project includes all medical practitioners in Olmsted County. 7 We identified all patients with encephalitis by searching the medical records from January 1, 1995 to December 31, 2015 for all potentially relevant diagnostic codes (Fig 1) .
Data Collection
Electronic and paper medical records were reviewed for demographic details (age, sex, race/ethnicity), period of follow-up, coexisting autoimmunity, clinical data, laboratory results, radiologic findings, and outcome at last follow-up using the modified Rankin score (mRS). All patients included had given consent for the passive use of their medical record for research purposes, and patients who did not authorize the use of their medical records for research were excluded.
Diagnostic Criteria
Diagnoses were assigned by 3 neurologists (D.D., E.P.F., A.S.L.-C.) from independent medical record review and categorized as infectious or autoimmune encephalitis. Autoimmune encephalitis diagnosis utilized criteria from a recent position paper on a clinical approach to this diagnosis. 6 The initial criteria to be met for consideration of possible autoimmune encephalitis include: (1) a compatible clinical syndrome of subacute/rapidly progressive altered mental status, memory loss, or psychiatric symptoms; (2) 1 or more of (A) focal central nervous system (CNS) findings, (B) new seizures, (C) cerebrospinal fluid (CSF) pleocytosis, and (D) magnetic resonance imaging (MRI) abnormalities consistent with autoimmune encephalitis; and (3) reasonable exclusion of other etiologies. 6 Patients with possible autoimmune encephalitis are then stratified via a diagnostic algorithm into specific subcategories of probable and definite autoimmune encephalitis including definite autoimmune encephalitis, autoantibody-defined disease (eg, antibodies against intracellular antigens, synaptic receptors, ion channels, or other cell surface proteins that strongly associate with autoimmune encephalitis), definite autoimmune limbic encephalitis, definite acute disseminated encephalomyelitis (ADEM), anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (probable and definite), Bickerstaff brainstem encephalitis (probable and definite), Hashimoto's encephalopathy (probable autoimmune), and autoantibody-negative but probable autoimmune encephalitis. 6 Patients with a final diagnosis of possible autoimmune encephalitis not meeting criteria for a probable or definite autoimmune encephalitis category were excluded.
Comparison Group of Infectious Encephalitis
For a comparison group, we evaluated the incidence and prevalence of infectious encephalitis including meningoencephalitis and progressive multifocal leukoencephalopathy (PML) per previously published criteria, 8, 9 but additionally we required confirmation of an infectious pathogen (bacterial/viral/fungal/ parasitic) for inclusion. Those with presumed infectious encephalitis without a confirmed pathogen or a prion disorder were excluded (see Fig 1) .
Neural Autoantibody Markers with High Specificity for Autoimmune Encephalitis
As outlined in the diagnostic criteria for autoimmune encephalitis, we only considered patients whose serum or CSF was positive for 1 or more IgG neural autoantibodies that strongly associate with and are highly specific for encephalitis as "autoantibody positive." The following autoantibody specificities were screened for by standardized indirect immunofluorescence assay (IFA): a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor (GluA1 and GluA2 subunits), amphiphysin, antineuronal nuclear antibody type 1 (ANNA1; anti-Hu), ANNA2 (anti-Ri), ANNA3, collapsin responsemediator protein 5 (CRMP5), contactin-associated protein 2 (CASPR2), dipeptidyl-peptidase-like protein 6 (DPPX), caminobutyric acid B (GABAB) receptor, glial fibrillary acidic protein (GFAP), glutamic acid decarboxylase 65kD isoform (GAD65), leucine-rich glioma-inactivated protein 1 (LGI1), Ma2 (performed through Athena Diagnostics, Marlborough, MA), metabotropic glutamate receptor 5 (mGluR5), NMDAR (GluN1 subunit), and Purkinje cell cytoplasmic autoantibody type 2/microtubule-associated protein 1B. 10,11 GAD65 IgG was assessed via radioimmunoprecipitation assay, and for this study GAD65 positivity was an inclusion criterion for the antibodypositive subgroup only if detected in CSF or if the serum titer exceeded 20nmol/l (normal 0.02nmol/l). 12 Cell-based assays (CBAs) using human embryonic kidney 293 cells transfected with appropriate expression plasmids were used to confirm AMPA receptor, CASPR2, DPPX, GABAB, mGluR5, LGI1 and NMDAR specificities (EUROIMMUN, L€ ubeck, Germany). IFA patterns consistent with GFAPa were confirmed similarly by in-house CBA.
11
Myelin oligodendrocyte glycoprotein (MOG) IgGs were detected by live in-house (Clinical Laboratory Improvement Amendments approved) fluorescence-activated cell sorting (FACS) assay. Patients seropositive for any unclassified neural autoantibody recognized in our Neuroimmunology Laboratory's unpublished experience to be strongly associated with autoimmune encephalitis were included in the "autoantibody-positive" group. We retested 13 specimens (11 sera, 2 CSF) for neural antibodies not tested at the time of service evaluation.
Neural Autoantibodies Not Highly Specific for Autoimmune Encephalitis
For this study, the following autoantibodies were considered not specific for autoimmune encephalitis and seropositivity for One patient had psychosis with a positive serum N-methyl-D-aspartate receptor (NMDAR) autoantibody but negative cerebrospinal fluid NMDAR autoantibody that resolved with antipsychotics alone; this patient was excluded. c Twenty-five of these patients were tested for neural antibodies and 4 were seropositive (see excluded patient section in methods). 1 or more of these antibodies was insufficient to be designated antibody positive: voltage-gated Kv1 potassium channelcomplex autoantibodies, but negative on subtyping for CASPR2 and LGI1 13 ; ganglionic acetylcholine receptor autoantibodies; GAD65 positivity in serum of lower serum titer (<20nmol/l); muscle acetylcholine receptor-binding autoantibody; N or P/Q type voltage-gated calcium channel autoantibodies; and striated muscle autoantibodies. 10 These patients were excluded and considered antibody negative for this study unless they had a coexisting antibody strongly associated with autoimmune encephalitis or they fulfilled the much more stringent criteria for probable or definite autoimmune encephalitis subcategories that do not require antibodies. 
Infectious Evaluation of CSF
Statistical Methodology
Patient and clinical characteristics were compared between autoimmune and infectious encephalitis subgroups using KruskalWallis or Fisher exact test, as appropriate. Age-and sex-specific population counts were obtained from the Rochester Epidemiology Project Census of Olmsted County for January 1, 2014 and annually for 1995 through 2015. Prevalence rates were calculated as the number of patients with autoimmune or infectious encephalitis (or their specific subgroups) divided by the population count as of January 1, 2014, and were reported per 100,000 people. The incidence rates were calculated as the number of patients with autoimmune or infectious encephalitis (or their specific subgroups) divided by the total number of person-years at risk and were reported per 100,000 person-years. These rates were adjusted using the direct method to the sex and age distribution of the total U.S. population in 2010.
Prevalence and incidence rates for autoimmune and infectious encephalitis were compared using generalized logit models in which the 3 patient levels were those that were disease free, those with autoimmune encephalitis, and those with infectious encephalitis. Prevalence and incidence rates for autoimmune encephalitis were separately calculated for non-Hispanic white (Caucasian) patients and for African-American patients using the corresponding race-specific Olmsted County population counts. Incidence rates were separately calculated within each encephalitis group and subgroup for 1995-2005 and for 2006-2015. Poisson regression models adjusted for age and sex were used to compare the race-specific rates as well as the incidence rates across the 2 time periods. Analyses were performed using SAS statistical software version 9.4 (SAS Institute, Cary, NC).
Excluded Patients with Encephalitis of Unknown Etiology and Immune-Related Disorders
Fifty-two patients with encephalitis of unknown etiology and immune-related disorders were excluded (see Fig 1) . Twentyfive of these patients were tested for neural antibodies, and 4 were seropositive for antibodies not specific for autoimmune encephalitis, including: voltage-gated potassium channel complex autoantibody negative for LGI1 and CASPR2 subtyping, n 5 2 (0.17nmol/l and 0.48nmol/l [normal 0.02]); ganglionic acetylcholine receptor autoantibody, n 5 1 (0.06nmol/l [normal-0.02]); and glutamic acid decarboxylase autoantibody, n 5 1 (0.06nmol/l [normal 0.02]). Eight excluded patients with possible autoimmune encephalitis received immunotherapy treatment trials, and 6 responded.
Results
Comparison of Autoimmune Encephalitis and Infectious Encephalitis
The prevalence and incidence rates for autoimmune and infectious encephalitis did not differ (respectively, 13.7 vs 11.6/100,000, p 5 0.63 and 0.8 vs 1.0/100,000 personyears, p 5 0.58; Tables 1 and 2 ). Autoimmune encephalitis prevalence slightly exceeded that of viral encephalitis, but the difference was not significant (13.7 vs 8.3/ 100,000, p 5 0.17); incident rates were about equivalent (0.8 [autoimmune] vs 0. 6 [viral] per 100,000 personyears, p 5 0.36). The number of relapses or recurrent hospitalizations was higher for autoimmune than infectious encephalitis (Table 3 ), but neither mRS at last follow-up nor the number of documented deaths differed significantly. Demographics and clinical data for the 2 patient groups are compared in Table 3 . The prevalence and incidence data for autoimmune encephalitis and infectious encephalitis, and their subgroups, are summarized in Tables 1 and 2 and Figure 2 (A, B) . Figure 3 shows MRI examples of autoimmune and infectious encephalitis etiologies.
Disproportionate African-American Ethnicity Representation in Autoimmune Encephalitis
The prevalence of autoimmune encephalitis was higher among the African-American population (38.3/100,000) than Caucasians (13.7/100,000, p 5 0.04), particularly for autoimmune GAD65 encephalitis (n 5 2) and ADEM (n 5 2 [1 patient was MOG-IgG positive]). The incidence of autoimmune encephalitis also was higher among African Americans (2.8/100,000 person-years) than Caucasians (0.7/100,000 person-years, p 5 0.01). The ethnic proportionality did not differ among incident/prevalent infectious encephalitis. 
Categories of Encephalitis for All Incident and Prevalent Autoimmune Encephalitis Cases
DEFINITE AUTOIMMUNE ENCEPHALITIS, AUTOANTI-GEN DESIGNATED. One or more neural-specific IgGs were detected in 13 autoimmune encephalitis cases; all 4 patients who were MOG-IgG positive in serum met criteria for ADEM, and 2 of them had coexisting serum GAD65 autoantibodies (0.06nmol/l, 0.15nmol/l [normal-0.02]). One, a boy aged 2 years at onset who was dual seropositive for NMDAR-IgG and MOG-IgG, had recurrent encephalitis, seizures, optic neuritis, and multifocal MRI abnormalities (see Fig 3A) . NMDAR-IgG was detected in CSF by CBA alone, and MOG-IgG was detected in serum by FACS (titer 5 100, [normal, <20]). Clinically, diagnostic criteria were met for autoimmune NMDAR encephalitis and ADEM; no tumor was found. . One patient with serum GFAPIgG positivity on tissue immunofluorescence confirmed by CBA using GFAPa isoform had the hallmark clinical syndrome of meningoencephalitis accompanied by bilateral optic disc edema, tremors, and radial enhancement on head MRI (see Fig 3B) , 14 and brain biopsy showed perivascular chronic inflammatory infiltrates, comprised mainly of mature T lymphocytes, microglial activation, and focal microglial nodules. One patient with limbic encephalitis accompanied by bilateral mesial temporal T2 hyperintensity with subsequent atrophy on MRI (see Fig 3C) was , had subacute cognitive decline and brainstem symptoms and signs. The serological findings prompted a search for cancer, leading to a diagnosis of seminoma in both cases.
DEFINITE AUTOIMMUNE LIMBIC ENCEPHALITIS.
Five patients without detectable neural autoantibodies met criteria for diagnosis of definite autoimmune limbic encephalitis (clinical criteria, n 5 5; bilateral MRI mesial temporal signal changes, n 5 5 [see Fig 3D] ; CSF pleocytosis, n 5 2; electroencephalographic criteria, n 5 3), and alternative etiologies were excluded. DEFINITE ADEM. Five patients without a detected neural autoantibody fulfilled diagnostic criteria for ADEM.
BICKERSTAFF ENCEPHALITIS.
No patients met diagnostic criteria for probable or definite Bickerstaff encephalitis.
HASHIMOTO'S ENCEPHALOPATHY. One patient met criteria for Hashimoto's encephalopathy, with encephalopathy, myoclonus, thyroid disease, thyroid peroxidase antibody seropositivity, normal MRI brain, no neural autoantibody detected in serum or CSF, and response to immunotherapy.
SERONEGATIVE PROBABLE AUTOIMMUNE ENCE-
PHALITIS. Four patients with a compatible clinical syndrome met at least 2 of the 3 criteria for this diagnosis: head MRI findings consistent with encephalitis (right medial temporal lobe T2/fluid-attenuated inversion recovery [FLAIR] hyperintensity, n 5 1; multifocal cortical T2/ FLAIR hyperintensities, n 5 1; multifocal subcortical T2/ FLAIR hyperintensities, n 5 2), CSF inflammation Cancer Associations of Autoimmune Encephalitis Six patients had paraneoplastic autoimmune encephalitis with the following neoplasms identified (3 after a predictive neural autoantibody profile was detected): breast carcinoma (n 5 2), seminoma (n 5 2; both were seronegative for Ma1 and Ma2 IgGs), thymoma (n 5 1), and lymphoma (n 5 1).
Treatments and Response in Autoimmune Encephalitis
Immunotherapy was administered to 26 of 28 patients (93%). High-dose corticosteroids (n 5 23), intravenous Ig (IVIG; n 5 2), and plasmapheresis (n 5 1) were the initial immunomodulatory therapies. Twenty-one (81%) improved clinically following immunotherapy, either as sole initial treatment (86%) or in combination with cancer therapy (14%). Thirteen patients (46%) received secondline or maintenance treatment (mycophenolate mofetil, n 5 4; cyclophosphamide, n 5 3; extended IVIG [ > 6 months], n 5 3; rituximab, n 5 2; extended prednisone course [>6 months], n 5 1).
Discussion
This study shows that the incidence and prevalence of autoimmune encephalitis approximates that of infectious encephalitis at a population level. Furthermore, the detection of autoimmune encephalitis is increasing over time. Although both infectious and autoimmune etiologies are associated with considerable morbidity, the tendency to relapse was greater in patients with autoimmune encephalitis, thus increasing the disease burden.
To our knowledge, this is the first study to determine the epidemiology of autoimmune encephalitis at a population level, showing an incidence of 0.8/100,000 person-years and prevalence of 13.7/100,000. Antibodypositive definite autoimmune encephalitis was the most prevalent category; next was ADEM. The most frequently identified neural autoantibody specificities were MOG and GAD65 (in CSF or in serum at high titer), with a single case of anti-NMDAR encephalitis identified with coexisting MOG-IgG. Prior epidemiological studies of encephalitis have mostly focused on infectious etiologies, with "immune-mediated" syndromes occasionally analyzed as a subgroup. Studies have utilized either administrative data, 2, 4 hospital evaluation data, or sample referral from selected hospitals to a centralized organization for epidemiological evaluation. 15 A prospective study of encephalitis in the United Kingdom that enrolled patients from 24 hospitals over a period of 2 years found infectious etiology to be twice as common as autoimmune etiology (42% vs 21% [the remainder were of uncertain etiology]); ADEM and NMDAR encephalitis were the most common subcategories. 16 A direct comparison to our study is limited, as that study was hospitalbased rather than truly population-based, the repertoire of antibodies available has expanded, and diagnostic criteria that we used were not available at that time. Additionally, among young patients tested at a referral laboratory for infectious encephalitis agents in California (the California Encephalitis Project), the frequency of NMDAR encephalitis was found to equate to viral causes in young individuals. 17 The incident rate of encephalitis (combined autoimmune and infectious) was lower than an Olmsted County study from 1950-1981 (1.8 vs 7.4/ 100,0000 person-years), reflecting our exclusion of encephalitis of unknown etiology and aseptic meningitis, the increased availability of vaccines in recent years, and access to MRI during our time period, which is very helpful in refining diagnosis. 18 Autoimmune encephalitis is a broad term that encompasses many different neurological diseases depending on the definition used; we used the 2016 diagnostic criteria for autoimmune encephalitis. 6 In utilizing these criteria, we took numerous steps to avoid an overestimate of autoimmune encephalitis frequency. First, only patients with probable or definite autoimmune encephalitis per the 2016 criteria were included (see Fig 1) . Second, diseases with more chronicity (eg, Morvan syndrome), clinical presentations different from classic limbic encephalitis (eg, progressive encephalomyelitis rigidity and myoclonus [PERM]), and immune-related disorders (eg, Rasmussen encephalitis [see Fig 1] ) were excluded per the 2016 diagnostic criteria. Third, only antibodies highly specific for autoimmune encephalitis (often detected by CBA) were included in the antibody-positive category and these antibodies are only rarely found in disease or healthy controls (0.2%). 19 Many patients designated antibody positive had CSF antibody detection, which is preferred for some antibodies (eg, NMDAR). However, antibody detection in serum alone can also be highly specific and may be required if CSF testing is not available (eg, MOG-IgG) or preferred if sensitivity is optimal in serum without loss of specificity (eg, serum LGI1 autoantibodies); all patients in this study with serum antibody positivity alone had syndromes compatible with autoimmune encephalitis. [20] [21] [22] With the exception of GAD65 (serum > 20nmol/l or detectable in CSF), patients with neural autoantibodies less specific for autoimmune encephalitis detected by older generation techniques (eg, immunoprecipitation assay) that can be found in controls (up to 6%) 19 were designated antibody negative for the purposes of this study. Such patients were excluded unless they had a coexisting highly specific antibody or they met more stringent criteria for antibody-negative autoimmune encephalitis. Care is needed in those with neural antibodies not strongly associated with autoimmune encephalitis (eg, voltage-gated potassium-channel autoantibodies negative for LGI1 and CASPR2), as a positive result can lead to premature diagnostic closure, an alternative diagnosis being overlooked, and iatrogenic morbidity from inappropriate immunosuppression. 6, 13, 23 A positive antibody test result should never replace clinical judgement. The 2016 diagnostic criteria focus on the limbic encephalitis phenotype. Patients with paraneoplastic/autoimmune encephalitis involving the brainstem alone (eg, accompanying Ma2 autoantibodies) may not meet criteria. Additionally, patients with faciobrachial dystonic seizures and LGI1 autoantibodies would not meet diagnostic criteria until cognitive impairment occurred, yet rapid diagnosis and early treatment may prevent cognitive impairment. 24 Future criteria need to consider how to best capture such cases, particularly if such criteria are to be used for enrollment in clinical trials. Treatment response was not a component of the 2016 criteria, which aimed at diagnosis prior to treatment and sought to distinguish autoimmune encephalitis from other steroidresponsive disorders (eg, lymphoma). However, this could result in underrepresentation of some autoimmune encephalitis cases, as 6 excluded patients met criteria for possible autoimmune encephalitis and responded to immunotherapy but lacked the classic features of limbic encephalitis required for inclusion in a subcategory of autoimmune encephalitis. The detection of autoimmune encephalitis is likely to increase over time, and the prevalence and incidence in our study are likely underestimates. This is evident by the tripling of its incidence from 1995-2005 to 2006-2015, markedly in antibody-positive cases (see Fig 2C) . Other contributors to underrepresentation may include the lack of widespread recognition of what we now recognize as classic syndromes (eg, neuropsychiatric syndrome of anti-NMDAR encephalitis, faciobrachial dystonic seizures in LGI1-antibody encephalitis) over the duration of our study , 25, 26 lack of availability of samples in those with encephalitis of unknown etiology, and the likelihood of further neural autoantibodies being discovered in the future. Infectious encephalitis may also be underrepresented because next generation sequencing for infectious agents was not available for this study. 27, 28 The higher incidence and prevalence of autoimmune encephalitis among African Americans is consistent with our prior reports of their predisposition for autoimmune GAD65 encephalomyelitis and for a similar CNS autoimmune disease, aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder. 29 This observation in autoimmune encephalitis is preliminary. Given that this population in general has less access to and receives lower quality medical care, 30 further study of populations with higher proportions of African Americans is needed. 31 Distinguishing paraneoplastic/autoimmune encephalitis from infectious or other etiologies can be difficult but is aided by laboratory testing for infectious/autoimmune etiologies and the presence of clinical and radiologic clues (see Fig 3) . As infectious meningoencephalitis and PML (which may lack accompanying inflammation) may mimic autoimmune encephalitis, these were included in the infectious category. Infection may be a trigger for CNS autoimmunity (eg, NMDAR encephalitis after HSV1 infection), although we did not encounter such cases in this study. 32, 33 Strengths of our study are, first, that Olmsted County is an excellent population for epidemiologic study due to its almost complete population coverage and long history of medical record collection. 31 Second, the availability of the Mayo Clinic Neuroimmunology Laboratory located within this county allowed comprehensive analysis and reanalysis of samples. Our study is limited by the lack of standardized testing for all infectious and autoimmune etiologies inherent in a population-based epidemiology study. Furthermore, differences in diagnostic criteria between infectious encephalitis (confirmation of pathogen) and autoimmune encephalitis (probable or definite by 2016 diagnostic criteria) could impact our comparison. When interpreting the frequency of specific autoantibodies, one must be mindful of the inherent variability of incidence/prevalence of rare disorders. For example, the detection rate for NMDAR autoantibody in the Mayo Neuroimmunology Service Laboratory (12/mo) is more frequent than for AMPAR autoantibody (2/mo), yet their incidence was equal in this population-based study.
In summary, this study shows that autoimmune encephalitis represents a large proportion of encephalitis whose detection is increasing over time. More populationbased studies of autoimmune encephalitis are needed to evaluate the frequency of these disorders in other populations.
